# Corbus Pharmaceuticals Holdings, Inc.: overview CRBP · Nasdaq · CIK 1595097 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/crbp.md) · [Financials](/companies/crbp/financials.md) · [Filings](/companies/crbp/filings.md) · [Insiders](/companies/crbp/insiders.md) Latest reported revenue: [$0](/filings/0000950170-23-006469.md) for Q4 FY2022, three months to 2022-12-31, from the 10-K filed Mar 7, 2023 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000950170-23-006469). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(1.15)](/filings/0001193125-25-277748.md) | not reported | [(1.39)](/filings/0001193125-26-219707.md) | [(1.44)](/filings/0001193125-26-338274.md) | [(1.90)](/filings/0001193125-25-277748.md) | not reported | [(1.23)](/filings/0001193125-26-219707.md) | [(1.81)](/filings/0001193125-26-338274.md) | | Free cash flow | $m | not reported | not reported | [(16.4)](/filings/0001193125-26-219707.md) | [(16.6) d](/filings/0001193125-26-338274.md) | not reported | not reported | [(25.6)](/filings/0001193125-26-219707.md) | [(29.6) d](/filings/0001193125-26-338274.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.9](/filings/0000950170-23-006469.md) | [0.0](/filings/0000950170-23-006469.md) | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(6350.1%)](/filings/0000950170-23-006469.md) | not reported | not reported | not reported | not reported | | Net margin | % | [(5176.4%)](/filings/0000950170-23-006469.md) | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(11.15)](/filings/0000950170-23-006469.md) | [(10.15)](/filings/0000950170-24-030133.md) | [(10.31)](/filings/0000950170-25-037335.md) | [(3.68)](/filings/0001193125-26-098530.md) | [(5.90)](/filings/0001193125-26-098530.md) | | Free cash flow | $m | [(48.2)](/filings/0000950170-23-006469.md) | [(37.6)](/filings/0000950170-24-030133.md) | [(36.1)](/filings/0000950170-25-037335.md) | [(41.8)](/filings/0001193125-26-098530.md) | [(64.5)](/filings/0001193125-26-098530.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/crbp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Cormorant Asset Management, LP](/funds/1583977.md) | 2026-06-30 | $22.0m | 2,344,971 | | Unchanged | | [ORBIMED ADVISORS LLC](/funds/1055951.md) | 2026-06-30 | $16.3m | 1,737,287 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $12.5m | 1,331,135 | | Added +1,059,499 | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $12.4m | 1,321,750 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.1m | 760,940 | | Added +26,834 | | [Jones Hill Capital LP](/funds/2102314.md) | 2026-06-30 | $6.1m | 653,572 | | New +653,572 | | [Prosight Management, LP](/funds/1617201.md) | 2026-06-30 | $6.1m | 650,000 | | Reduced −47,108 | | [DIADEMA PARTNERS LP](/funds/2026172.md) | 2026-06-30 | $5.9m | 633,800 | Call | Added +518,500 | | [Caption Management, LLC](/funds/1706766.md) | 2026-06-30 | $5.4m | 572,300 | Call | New +572,300 | | [Stonepine Capital Management, LLC](/funds/1440771.md) | 2026-06-30 | $4.0m | 425,000 | | Added +41,538 | ## Recent filings [All 799 filings](/companies/crbp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-15 | 10:27 ET | [8-K](/filings/0001193125-26-422437.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-422437 | | 2026-09-14 | 07:06 ET | [8-K](/filings/0001193125-26-389829.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-389829 | | 2026-08-06 | 16:35 ET | [10-Q](/filings/0001193125-26-338274.md) | Quarterly report, period 2026-06-30 | 0001193125-26-338274 | | 2026-08-06 | 08:15 ET | [8-K](/filings/0001193125-26-336864.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-336864 | | 2026-07-06 | 08:15 ET | [8-K](/filings/0001193125-26-295622.md) | 1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-295622 | | 2026-05-26 | 08:56 ET | [8-K](/filings/0001193125-26-238059.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-238059 | | 2026-05-21 | 08:15 ET | [8-K](/filings/0001193125-26-233507.md) | 1.01 Entry into a material agreement; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-233507 | | 2026-05-14 | 08:15 ET | [8-K](/filings/0001193125-26-222890.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-222890 | | 2026-05-12 | 16:50 ET | [10-Q](/filings/0001193125-26-219707.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219707 | | 2026-05-12 | 08:15 ET | [8-K](/filings/0001193125-26-218250.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-218250 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-098530.md), filed Mar 9, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1595097 - Tickers: CRBP - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 11:04 ET. No prices; not investment advice.